Low‐density lipoprotein cholesterol (mg/dL) (endpoint low‐density lipoprotein cholesterol reading) · people with established arterial occlusive events
1 finding from 1 review
Blood pressure · people with established arterial occlusive events
1 finding from 1 review
Heart rate · people with established arterial occlusive events
1 finding from 1 review
Change in depression score ( · adolescents and adults with congenital heart disease
2 findings from 1 review
All‐cause mortality · people with AHF
It is very uncertain whether ultrafiltration (UF) changes all‐cause mortality compared with usual care (UC) (very low certainty).
1 finding from 1 review
Patient readmissions · people with AHF
Ultrafiltration (UF) showed no clear difference in all‐cause rehospitalisation compared with usual care (UC) (low certainty).
1 finding from 1 review
Heart failure‐related rehospitalisation · people with AHF
Ultrafiltration (UF) showed no clear difference in heart failure‐related rehospitalisation compared with usual care (UC) (low certainty).
1 finding from 1 review
Need for mechanical invasive ventilation – up to and including 30 days · people with AHF
1 finding from 1 review
% Change in serum creatinine – at 30 days from discharge · people with AHF
1 finding from 1 review
New initiation of renal replacement therapy – at longest available · people with AHF
Ultrafiltration (UF) showed no clear difference in new initiation of renal replacement therapy – at longest available compared with usual care (UC) (low certainty).
1 finding from 1 review
Complications of central line insertion – in hospital · people with AHF
It is very uncertain whether ultrafiltration (UF) changes complications of central line insertion – in hospital compared with usual care (UC) (very low certainty).
1 finding from 1 review
Objective measure of medication adherence: Cholesterol (low‐density lipoprotein) · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Objective measure of medication adherence: Blood pressure · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Combined cardiovascular events · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Adverse events · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Cognitive outcome: satisfaction with treatment · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in cardiovascular mortality (RR) Median compared with usual care (moderate certainty).
1 finding from 1 review
Time to first hospitalisation for heart failure during · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in heart failure hospitalisation, first (RR) Range of compared with usual care (moderate certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in hyperkalaemia Range of compared with usual care (moderate certainty).
1 finding from 1 review
All‐cause mortality (RR) Range of · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) leads to lower all‐cause mortality (RR) Range of compared with usual care (high certainty).
1 finding from 1 review